Revolution Medicines Q1 net loss $116M; cash $1.70B; plans pivotal RMC-6236 trials in H2 2024

Revolution Medicines, Inc.

2024-Q1 EPS reported -$0.70

Net loss of $116.0M for Q1 2024, compared to $68.1M in Q1 2023.
Revenue $0 (ended Sanofi collaboration); R&D expenses $118.0M (up from $68.9M).
Cash $1.70B as of March 31, 2024; projected cash runway into 2027.
Plans to initiate two pivotal monotherapy trials of RMC-6236 in 2L PDAC and 2L NSCLC in H2 2024.
Reiterates FY2024 GAAP net loss guidance between $480M and $520M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Revolution Medicines, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.